In this study patients with diabetes (3570 subjects) which were at high cardiovascular risks, with hypertension or already on antihypertensive therapy, initially were randomized either to ramipril ( increasing to 10 mg daily) or to placebo.

In those randomized to ramipril there was 25% lower risk of macrovascular disease and 37% lower risk of cardiovascular death.